Abiraterone Acetate
Enzyme Inhibitors
Eli Lilly and CompanyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Enzyme Inhibitors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Eli Lilly and Company | Phase 3 | B |
Abemaciclib Eli Lilly and Company | Phase 3 | B |
VOLITINIB AstraZeneca | Phase 3 | B |
PREDNISONE TABLETS Eli Lilly and Company | Phase 3 | B |
su011248 AstraZeneca | Phase 3 | B |
(+)-VINCRISTINE Xiaoxiang Chen | Phase 2 | CCC |
Niraparib Xiaoxiang Chen | Phase 2 | CCC |
Irinotecan Xiaoxiang Chen | Phase 2 | CCC |
Same molecule, other indications
Abiraterone Acetate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →